Kisqali (Ribociclib)

Ribociclib selectively blocks cyclin‑dependent kinases 4 and 6, which are essential for cell‑cycle transition from G1 to S phase. By preventing this phosphorylation step, the drug halts tumor cell proliferation, particularly in cancers that depend on CDK4/6 signaling, such as hormone‑driven breast cancer.

The prescribed dose of Kisqali is determined by the treating physician based on the patient’s clinical condition and treatment plan. A common regimen involves 600 mg taken orally once daily for 21 days followed by a 7‑day break in a 28‑day cycle, but exact dosing must be individualized by the prescriber.

Safety of ribociclib in pregnancy and lactation has not been established. The drug may cause fetal harm, so it is contraindicated in pregnant women. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended.

To order Kisqali, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kisqali (ribociclib) shares the CDK4/6 inhibition mechanism with palbociclib and abemaciclib but differs in dosing schedules, side‑effect profiles, and specific drug‑interaction potentials. Ribociclib has a longer half‑life, allowing once‑daily dosing, and is associated with a higher incidence of hepatotoxicity, whereas abemaciclib is taken twice daily and may cause more gastrointestinal toxicity.

Kisqali tablets should be stored at room temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Do not refrigerate or freeze the product. Keep it out of reach of children and store in a dry place away from direct sunlight.

Kisqali is taken orally as a tablet, usually with water. It is commonly prescribed to be taken on an empty stomach, but patients should follow the specific instructions provided by their healthcare professional regarding timing relative to meals and other medications.

The most serious risks include severe neutropenia or febrile neutropenia, liver toxicity (elevated transaminases), QT‑interval prolongation leading to cardiac arrhythmias, and serious infections. Patients should report symptoms such as fever, persistent fatigue, jaundice, palpitations, or unexplained shortness of breath to their physician promptly.

Kisqali should not be used in patients with severe hepatic impairment, uncontrolled QT prolongation, or those taking strong CYP3A4 inhibitors that cannot be discontinued. It is also contraindicated in pregnant women and not recommended for breastfeeding mothers. Patients with a history of serious cardiac arrhythmias or uncontrolled infections should avoid the drug.